| Literature DB >> 24586536 |
Stefan Monecke1, Bettina Stieber1, Rashida Roberts2, Patrick Eberechi Akpaka2, Peter Slickers3, Ralf Ehricht3.
Abstract
It has been shown previously that high rates of methicillin- and mupirocin-resistant Staphylococcus aureus exist in the Caribbean islands of Trinidad and Tobago, as well as a high prevalence of Panton-Valentine leukocidin-positive S. aureus. Beyond these studies, limited typing data have been published. In order to obtain insight into the population structure not only of MRSA but also of methicillin-susceptible S. aureus, 294 clinical isolates collected in 2012/2013 were typed by microarray hybridisation. A total of 15.31% of the tested isolates were MRSA and 50.00% were PVL-positive. The most common MSSA strains were PVL-positive CC8-MSSA (20.41% of all isolates tested), PVL-positive CC152-MSSA (9.52%) and PVL-positive CC30-MSSA (8.84%) while the most common MRSA were ST239-MRSA-III&SCCmer (9.18%) and ST8-MRSA-IV, "USA300" (5.78%). 2.38% of characterised isolates belonged to distinct strains likely to be related to "Staphylococcus argenteus" lineages. The population structure of S. aureus isolates suggests an importation of strains from Africa, endemicity of PVL-positive MSSA (mainly CC8) and of ST239-MRSA-III, and a recent emergence of the PVL-positive CC8-MRSA-IV strain "USA300".Entities:
Mesh:
Substances:
Year: 2014 PMID: 24586536 PMCID: PMC3929661 DOI: 10.1371/journal.pone.0089120
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1SplitsTree graph visualising strain assignments and similarities between isolates.
Isolates were numbered as in file S1. mecA positives are indicated with squares, PVL-positives with crosses.
Genes associated with antimicrobial resistance.
| Gene | Gene product/explanation | All isolates | MSSA only | MRSA only |
|
| Alternate penicillin binding protein 2, defining MRSA | 45 (15.31%) | 0 | 45 (100%) |
|
| Cassette chromosome elements SCC | 0 | 0 | 0 |
|
| 0 | 0 | 0 | |
|
| 25 (8.5%) | 0 | 25 (55.56%) | |
|
| 2 (0.68%) | 0 | 2 (4.44%) | |
|
| 15 (5.10%) | 0 | 15 (33.33%) | |
|
| 2 (0.68%) | 0 | 2 (4.44%) | |
|
| 1 (0.34%) | 0 | 1 (2.22%) | |
|
| Mercury resistance operon | 31 (10.54%) | 4 (1.61%) | 27 (60%) |
|
| Beta-lactamase operon | 254 (86.39%) | 211 (84.74%) | 43 (95.56%) |
|
| Methyltransferases, erythromycin/clindamycin resistance | 29 (9.86%) | 2 (0.80%) | 27 (60%) |
|
| 0 | 0 | 0 | |
|
| 0 | 0 | 0 | |
|
| Lincosamid-nucleotidyltransferase | 1 (0.34%) | 1 (0.4%) | 0 |
|
| Macrolide efflux protein A | 0 | 0 | 0 |
|
| Probable lysylphosphatidylglycerol synthetase | 21 (7.14%) | 4 (1.61%) | 17 (37.78%) |
|
| Energy dependent efflux of erythromycin | 24 (8.16%) | 7 (2.81%) | 17 (37.78%) |
|
| Bifunctional enzyme Aac/Aph, gentamicin resistance | 28 (9.52%) | 0 | 28 (62.22%) |
|
| Aminoglycoside adenyltransferase, tobramycin resistance | 12 (4.08%) | 7 (2.81%) | 5 (11.11%) |
|
| Aminoglycoside phosphotransferase, neo-/kanamycin resist. | 45 (15.31%) | 2 (0.80%) | 43 (95.56%) |
|
| Fusidic acid resistance gene ( = | 1 (0.34%) | 1 (0.4%) | 0 |
|
| Fusidic acid resistance gene from “SCC | 2 (0.68%) | 2 (0.8%) | 0 |
|
| Mupirocin resistance protein | 17 (5.78%) | 9 (3.61%) | 8 (17.78%) |
|
| Tetracycline resistance | 29 (9.86%) | 6 (2.41%) | 23 (51.11%) |
|
| Tetracycline resistance | 30 (10.20%) | 3 (1.20%) | 27 (60%) |
|
| Chloramphenicol acetyltransferase | 2 (0.68%) | 1 (0.40%) | 1 (2.22%) |
|
| Chloramphenicol/florfenicol exporter | 0 | 0 | 0 |
|
| Linezolid resistance | 0 | 0 | 0 |
|
| Dihydrofolate reductase type 1 | 1 (0.34%) | 1 (0.4%) | 0 |
|
| Quaternary ammonium compound resistance protein A | 22 (7.48%) | 3 (1.2%) | 19 (42.22%) |
|
| Quaternary ammonium compound resistance protein C | 9 (3.06%) | 6 (2.41%) | 3 (6.67%) |
|
| Streptothricine-acetyltransferase | 45 (15.31%) | 2 (0.80%) | 43 (95.56%) |
|
| Vancomycin resistance gene | 0 | 0 | 0 |
Genes associated with virulence.
| Gene | Gene product/explanation | All isolates | MSSA only | MRSA only |
|
| Accessory gene regulator allele I | 206 (70.07%) | 162 (65.06%) | 44 (97.78%) |
|
| Accessory gene regulator allele II | 36 (12.24%) | 35 (14.06%) | 1 (2.22%) |
|
| Accessory gene regulator allele III | 33 (11.22%) | 33 (13.25%) | 0 |
|
| Accessory gene regulator allele IV | 12 (4.08%) | 12 (4.82%) | 0 |
|
| Unidentified | 7 (2.38%) | 7 (2.81%) | 0 |
|
| Toxic shock syndrome toxin 1 | 5 (1.70%) | 5 (2.01%) | 0 |
|
| Enterotoxin A | 36 (12.24%) | 15 (6.02%) | 21 (46.67%) |
|
| Enterotoxin A ( = P), allele from N315 | 14 (4.76%) | 14 (5.62%) | 0 |
|
| Enterotoxin B | 24 (8.16%) | 24 (9.64%) | 0 |
|
| Enterotoxin C and L | 20 (6.80%) | 20 (8.03%) | 0 |
|
| Enterotoxin D | 63 (21.43%) | 63 (25.30%) | 0 (0%) |
|
| Enterotoxin E | 0 | 0 | 0 |
|
| Enterotoxin H | 5 (1.70%) | 5 (2.01%) | 0 |
|
| Enterotoxin J | 64 (21.77%) | 64 (25.70%) | 0 |
|
| Enterotoxin K and Q | 110 (37.41%) | 67 (26.91%) | 43 (95.56%) |
|
| Enterotoxin R | 63 (21.43%) | 63 (25.30%) | 0 |
|
|
| 90 (30.61%) | 89 (35.74%) | 1 (2.22%) |
|
| Enterotoxin homologue | 15 (5.10%) | 15 (6.02%) | 0 |
|
| Panton-Valentine leukocidin | 147 (50%) | 130 (52.21%) | 17 (37.78%) |
|
| Staphylokinase | 255 (86.73%) | 218 (87.55%) | 37 (82.22%) |
|
| Chemotaxis inhibiting protein (CHIPS) | 158 (53.74%) | 142 (57.03%) | 16 (35.56%) |
|
| Staphyl. complement inhibitor | 266 (90.48%) | 229 (91.97%) | 37 (82.22%) |
|
| Exfoliative toxin serotype A | 11 (3.74%) | 11 (4.42%) | 0 |
|
| Exfoliative toxin serotype B | 5 (1.70%) | 5 (2.01%) | 0 |
|
| Exfoliative toxin D | 0 | 0 | 0 |
|
| Epidermal cell differentiation inhibitor | 13 (4.42%) | 13 (5.22%) | 0 |
|
| Epidermal cell differentiation inhibitor B | 27 (9.18%) | 27 (10.84%) | 0 |
|
| Epidermal cell differentiation inhibitor C | 4 (1.36%) | 4 (1.61%) | 0 |
|
| ACME locus | 18 (6.12%) | 0 | 18 (40%) |
|
| Collagen adhesin | 136 (46.26%) | 109 (43.78%) | 27 (60%) |
|
| Staphylococcal protein G | 198 (67.35%) | 153 (61.45%) | 45 (100%) |
|
| Capsule type 8 alleles | 166 (56.46%) | 148 (59.44%) | 18 (40%) |
|
| Capsule type 5 alleles | 122 (41.50%) | 95 (38.15%) | 27 (60%) |
|
| Unidentified capsule type or negatives | 6 (2.04%) | 6 (2.41%) | 0 |
Typing data.
| CC | Strain | N (%) |
|
| CC1-MSSA | 5 (1.70%) |
|
| CC5-MSSA | 8 (2.72%) |
| CC5-MSSA [PVL+] | 14 (4.76%) | |
| CC5-MRSA-V [ACME+] | 1 (0.34%) | |
|
| CC6-MSSA | 12 (4.08%) |
| CC6-MSSA [PVL+] | 2 (0.68%) | |
|
| CC7-MSSA | 4 (1.36%) |
|
| CC8-MSSA | 13 (4.42%) |
| CC8-MSSA [PVL+] | 60 (20.41%) | |
| ST8-MRSA-IV [PVL+/ACME+] | 15 (5.10%) | |
| ST8-MRSA-IV [PVL+/ACME+, truncated SCC | 2 (0.68%) | |
| ST72-MSSA | 14 (4.76%) | |
| ST72-MSSA-SCC | 1 (0.34%) | |
| ST72-MSSA-SCC | 1 (0.34%) | |
| ST239-MRSA-III&SCC | 25 (8.50%) | |
| ST239-MRSA-III+ | 2 (0.68%) | |
|
| ST834-MSSA | 1 (0.34%) |
|
| CC12-MSSA | 3 (1.02%) |
|
| CC15-MSSA | 10 (3.40%) |
|
| CC20-MSSA | 1 (0.34%) |
|
| CC30-MSSA | 1 (0.34%) |
| CC30-MSSA [PVL+] | 26 (8.84%) | |
|
| CC45-MSSA | 10 (3.40%) |
|
| CC97-MSSA | 5 (1.70%) |
|
| CC101-MSSA | 3 (1.02%) |
|
| CC121-MSSA | 12 (4.08%) |
|
| CC152-MSSA [PVL+] | 28 (9.52%) |
|
| CC188-MSSA | 5 (1.70%) |
|
| CC398-MSSA | 2 (0.68%) |
|
| ST1852-MSSA | 1 (0.34%) |
|
| CC1223/1594-MSSA | 1 (0.34%) |
|
| ST2250/2277-MSSA | 5 (1.70%) |
| ST2596dlv-MSSA | 1 (0.34%) |